| Filed On | Filing |
|---|---|
| 29 Oct 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Raises 2026 Revenue Guidance to $520 Million to $530 Million and Adjusted EBITDA Guidance to $90 Million to $100 Million |
| 30 Jul 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Raises 2026 Revenue Guidance to $490 Million to $500 Million and Raises 2026 AEBITDA Guidance to $66 Million to $78 Million |
| 07 Jul 2026 |
8-K: Completion of Acquisition or Disposition of Assets; Regulation FD Disclosure
Sharpens focus on U.S. precision medicine Testing Services and Patient & Digital Solutions |
| 15 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
This Amendment No 2. (this “Amendment”) to the CareDx, Inc. 2024 Equity Incentive Plan (as previously amended by Amendment No. 1, the “Plan”) was adopted by the Board of Directors (the “Board”) of CareDx, Inc. (the “Company”), and follow... |
| 28 Apr 2026 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +2 more
[***] Certain information in this document has been omitted from this exhibit pursuant to Item 601(b) of Regulation S-K because it is both not material and is the type that the Registrant treats as private or confidential. |
| 16 Apr 2026 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +1 more
Sections 1.1, 5.12(a), 5.12(b), 5.12(d), 5.12(f), 5.12(g), 5.12(i) and 5.12(j) |
| 24 Feb 2026 |
8-K: Results of Operations and Financial Condition
Full Year 2025 Total Revenue of $380 Million Increased 14% Year-Over-Year |
| 12 Jan 2026 |
8-K: Results of Operations and Financial Condition
Expects Fourth Quarter Revenue Growth of Approximately 25% Year-Over-Year |
| 18 Dec 2025 |
8-K: Other Events
THE ROSEN LAW FIRM, P.A.Laurence M. Rosen (SBN 219683)355 S. Grand Avenue, Suite 2450Los Angeles, California 90071Telephone: (213) 785-2610Facsimile: (213) 226-4684Email: [email protected] |
| 15 Dec 2025 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year
The registered office of CareDx, Inc. shall be fixed in the corporation’s certificate of incorporation. References in these bylaws to the certificate of incorporation shall mean the certificate of incorporation of the corporation, as ame... |
| 04 Nov 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Grew Testing Services Volume to Approximately 50,300, Increase of 13% Year-Over-Year |
| 24 Oct 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On and effective as of October 22, 2025, the Board of Directors (the “Board”) or CareDx, Inc. (the “Company”) appointed Suresh Gunasekaran as a Class II director of the Company. As of the time of this filing, the Board has not made a fin... |
| 06 Aug 2025 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation +1 more
Grew Testing Services Volume to Approximately 49,500, Increase of 13% Year-Over-Year |
| 12 Jun 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
This Amendment No 1. (this “Amendment”) to the CareDx, Inc. 2024 Equity Incentive Plan (the “Plan”) was adopted by the Board of Directors (the “Board”) of CareDx, Inc. (the “Company”), and following the Board’s approval of this Amendment... |
| 03 Jun 2025 |
8-K: Regulation FD Disclosure; Other Events
Board of Directors Authorizes New $50 Million Share Repurchase Program |
| 30 Apr 2025 |
8-K: Results of Operations and Financial Condition
First Quarter Revenue of $84.7 Million, Increased 18% Year-Over-Year |
| 28 Mar 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
This Amended and Restated Change of Control and Severance Agreement (this “Agreement”) is made and entered into by and between Abhishek Jain (“Executive”) and CareDx, Inc., a Delaware corporation (the “Company”), effective as of March 27... |
| 26 Feb 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Expects Full Year 2025 Revenue of $365 Million to $375 Million |
| 13 Jan 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
BRISBANE, Calif. — (BUSINESS WIRE)—January 13, 2025, CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – today reported preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2024. |
| 08 Jan 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
CareDx, Inc. (the “Company”) believes that the granting of equity and cash compensation to its members of the Board of Directors (the “Board,” and members of the Board, the “Directors”) represents an effective tool to attract, retain and... |
Loading...